We have examined the capacity of a live avirulent mutant form of the intracellular bacterial pathogen Legionella pneumophila to induce immune responses and protective immunity in guinea pigs. The mutant L. pneumophila is nonlethal to guinea pigs and does not revert to virulence with passage through guinea pigs. In contrast, exposure of guinea pigs to aerosols containing wild-type L. pneumophila induces a pneumonic illness that clinically and pathologically resembles Legionnaires' disease in humans. Guinea pigs immunized by aerosol exposure to mutant L. pneumophila developed a strong humoral immune response to wild-type L. pneumophila antigens with reciprocal antibody titers of 32-512 (median 256) by the indirect fluorescent antibody assay, compared with titers of < 2 for control (sham immunized) guinea pigs. Mutant immunized but not control guinea pigs also developed strong cell-mediated immune responses to wild-type L. pneumophila antigens, as demonstrated in assays of cutaneous delayed-type hypersensitivity and in vitro splenic lymphocyte proliferation.
Legionella pneumophila is a facultative intracellular bacterial pathogen and the causative agent of Legionnaires' disease, a serious and often fatal form of pneumonia (1) . Patients with Legionnaires' disease develop both humoral and cell-mediated immune responses to L. pneumophila (2) (3) (4) . Cell-mediated immunity appears to play a primary role in host defense, as activated human monocytes and alveolar macrophages inhibit the intracellular multiplication of L. pneumophila (4) (5) (6) . Humoral immunity appears to play a secondary role in host defense (2, 3) .
The guinea pig is an excellent animal model for the study of Legionnaires' disease. When exposed to aerosols containing L. pneumophila guinea pigs develop a pneumonic illness that is clinically and pathologically similar to Legionnaires' disease in humans (7-1 1) . A previous study from this laboratory demonstrated that guinea pigs immunized by a sublethal dose of aerosolized L. pneumophila develop humoral and cell-mediated immune responses and protective immunity to subsequent challenge with a lethal aerosol dose of L. pneumophila (12).
Another study from this laboratory described an avirulent mutant form of L. pneumophila that survives but does not multiply in human monocytes (13) . Like the wild-type, the mutant enters monocytes by coiling phagocytosis (13, 14) . Thereafter, however, the mutant follows an intracellular pathway that differs from the wild-type. Whereas the wild-type phagosome interacts sequentially with host cell smooth vesicles, mitochondria, and ribosomes, a process culminating in the formation of a ribosome-lined replicative phagosome, the mutant phagosome does not interact with these host cell organelles (13) . Moreover, whereas the wild-type phagosome does not fuse with lysosomes, the mutant phagosome does fuse with lysosomes so that the mutant comes to reside in a phagolysosome (13) . In all other aspects examined the mutant resembles the wild-type. Both organisms are resistant to complement in the presence or absence of anti-L. pneumophila antibody. Both organisms have similar colony morphology, ultrastructure, and structural and secretory protein profiles and lipopolysaccharide profiles on analysis by PAGE. Serology. Anti-L. pneumophila antibody in the serum of guinea pigs immunized once or twice with mutant L. pneumophila or in the serum of control guinea pigs was assayed by the indirect fluorescent antibody technique as described for human serum by Wilkinson et al.
Methods
(15). Antigen-bearing slide wells were prepared by covering each well ofa 12-well microscope slide (Cel-Line Associates, Minotola, NJ) with 15 ul of a suspension containing 2 X I07 FKLP/ml. The slides were air dried, fixed in acetone for 15 min, and then air-dried again. Serum obtained by cardiac puncture from guinea pigs was serially diluted twofold in PBS up to a concentration of 1:1,024, and 20 Ml of each concentration was applied to each well. The slides were incubated at 370C in 100% humidity for 30 min, rinsed, and then soaked in PBS. 10
Ml of fluorescein-conjugated IgG fraction goat anti-guinea pig IgG (Fc fragment) (Cappel Laboratories, Cochranville, PA) was placed on each well and the slides were then incubated at 370C in 100% humidity for 30 min and rinsed with PBS. The slides were magnified 1,000 times with a fluorescence microscope (Nikon Inc., Garden City, NY). The titer of each animal's serum was expressed as the reciprocal of the dilution that produced 2+ fluorescent staining of at least 50% of the FKLLP in a microscopic field.
Cutaneous delayed-type hypersensitivity. Guinea pigs were shaved over the back and flank and administered 100 ul of FKLP diluted in EYB to a concentration of 108 or I09 bacterial particles/ml or 100 Ml of control buffer (EYB) intradermally at different sites in the shaved area. The diameters of areas of erythema and induration at these sites were recorded at 24, 48, and 72 h after injection.
Lymphocyte proliferation assay. Splenic lymphocytes from mutant immunized or control guinea pigs were obtained and purified, incubated with antigens (L. pneumophila membranes or FKLP) in triplicate microtest wells for 2 d, and then tested for capacity to incorporate
[3H]thymidine as described (12).
Studies ofprotective immunity. Guinea pigs were immunized once or twice by exposure to an aerosol generated from a 10-ml suspension containing 5 X 109 CFU/ml of mutant L. pneumophila or 2.5 X 106 CFU/ml of wild-type L. pneumophila (sublethal dose). Where guinea pigs were immunized twice, the second immunization was 3 wk after the first. Control guinea pigs were sham immunized once or twice. 3 wk after immunization all guinea pigs were challenged with an aerosolized dose ofwild-type L. pneumophila. The challenge dose ofwild-type L. pneumophila (2.5 X 108 CFU/ml), hereinafter referred to as one lethal dose (LD,1 ), was the lowest dose that consistently resulted in the death of all control guinea pigs (12). After the challenge the number of survivors in each group of animals was quantitated. Differences In four experiments involving nine pairs of mutant immunized and control guinea pigs, the mutant immunized animals consistently had significantly greater splenic lymphocyte proliferative responses to L. pneumophila antigens than did control animals (Table III) 
